Overview / Abstract: |
Early diagnosis is key to improving outcomes in patients with MS. Initiating disease-modifying therapy (DMT) as soon as possible is essential to control disease symptoms, mitigate progression and prevent relapse, and minimize disease-related disability. An improved understanding of MS pathophysiology has revolutionized the DMT landscape, offering patients more than 15 approved therapies. However, difficulties remain in ensuring an accurate diagnosis and individualizing therapy for each patient, which may preclude patients from reaping the optimal benefits of therapy. This activity, "Reducing Disease Activity in Multiple Sclerosis: Keeping Up with Recent Advances," will provide clinicians with a concise, but comprehensive, review of approved DMTs for MS, illustrations of appropriate assessments, determinations of MS subtypes, identifications of prognostic factors, and determinations of patients’ risks for progression. It will also provide communication techniques and patient-engagement strategies that enable clinician/patient collaborations, improve treatment compliance, and enhance patient quality of life. |
Expiration |
Jun 03, 2021 |
Discipline(s) |
Physician CME |
Format |
Online, Webinar / Webcast / Video |
Credits / Hours |
1.0 AMA PRA Category 1 Credit™ |
Accreditation |
ACCME |
Presenters / Authors / Faculty |
PATRICIA K. COYLE, MD, FAAN, FANA SUHAYL DHIB-JALBUT, MD |
Activity Specialities / Related Topics |
Neurology, Primary Care |
Sponsors / Supporters / Grant Providers |
This activity has been supported by educational grants from Biogen and Sanofi Genzyme. |
Keywords / Search Terms |
Rockpointe Rockpointe MS, Multiple Sclerosis, Free CME, Free CE, CME, PSU, Penn State Free CE CME |